The Chemours Company (NYSE:CC) Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp increased its position in The Chemours Company (NYSE:CC - Free Report) by 22.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 526,848 shares of the specialty chemicals company's stock after buying an additional 95,814 shares during the quarter. Mackenzie Financial Corp owned 0.35% of Chemours worth $16,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Legacy Financial Group LLC bought a new position in shares of Chemours during the third quarter valued at about $29,000. Morton Brown Family Wealth LLC bought a new position in shares of Chemours in the fourth quarter worth approximately $35,000. Atlas Capital Advisors LLC purchased a new position in shares of Chemours in the second quarter worth $52,000. Anchor Investment Management LLC bought a new stake in Chemours during the 4th quarter valued at $56,000. Finally, Geneos Wealth Management Inc. boosted its position in Chemours by 116.4% during the 4th quarter. Geneos Wealth Management Inc. now owns 1,859 shares of the specialty chemicals company's stock valued at $59,000 after buying an additional 1,000 shares during the period. Hedge funds and other institutional investors own 76.26% of the company's stock.

Wall Street Analyst Weigh In

CC has been the topic of a number of analyst reports. BMO Capital Markets upgraded shares of Chemours from an "underperform" rating to an "outperform" rating and boosted their price objective for the company from $19.00 to $34.00 in a research report on Tuesday, April 9th. Barclays lowered their price target on Chemours from $32.00 to $30.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 2nd. Finally, UBS Group lifted their price objective on Chemours from $21.00 to $28.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 2nd. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $30.89.

Chemours Stock Down 2.2 %

Shares of NYSE CC traded down $0.57 during mid-day trading on Friday, hitting $25.91. 899,985 shares of the stock traded hands, compared to its average volume of 1,893,876. The company has a market cap of $3.86 billion, a price-to-earnings ratio of -16.72 and a beta of 2.00. The stock has a fifty day moving average price of $26.90 and a 200-day moving average price of $27.79. The Chemours Company has a 52 week low of $15.10 and a 52 week high of $39.05. The company has a debt-to-equity ratio of 5.40, a quick ratio of 1.00 and a current ratio of 1.54.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Monday, February 26th were given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 3.86%. The ex-dividend date of this dividend was Friday, February 23rd. Chemours's dividend payout ratio is presently -64.52%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.